Immunic Q1 Earnings Miss Expectations with EPS of -$1.08
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Source: seekingalpha
- Earnings Performance: Immunic reported a Q1 GAAP EPS of -$1.08, missing expectations by $0.12, indicating challenges in profitability that could affect investor confidence.
- Cash Reserves: As of March 31, 2026, Immunic had cash and cash equivalents of $186.6 million, which is expected to fund operations into late 2027, reflecting some flexibility in financial management.
- Impact of Financing Activities: The recent $400 million private placement provides crucial funding for R&D and operations, suggesting that despite short-term financial struggles, the company has long-term growth potential.
- Market Reaction: Immunic's stock rose following a new Buy rating from Guggenheim, indicating market confidence in its lead asset, even though overall financial data was disappointing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMUX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMUX
Wall Street analysts forecast IMUX stock price to fall
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.300
Low
3.00
Averages
4.25
High
8.00
Current: 12.300
Low
3.00
Averages
4.25
High
8.00
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunic Appoints New Chair of Board of Directors
- Leadership Change: Immunic, Inc. appointed Mike Bonney as Chair of the Board effective May 16, 2026, succeeding Interim Chair Simona Skerjanec; Bonney brings over 30 years of leadership experience in the biopharmaceutical industry, particularly in multiple sclerosis, which is expected to drive the company towards commercialization.
- Proven Success: Bonney's previous role at Biogen involved senior commercial leadership and the launch of Avonex®, a foundational therapy for multiple sclerosis, and this experience is anticipated to support Immunic's regulatory approval and market readiness for vidofludimus calcium.
- Market Potential: Immunic's vidofludimus calcium is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026; Bonney's addition is expected to enhance the company's competitiveness in this rapidly growing market.
- Strategic Development: Bonney's successful tenure at Cubist Pharmaceuticals, where he led the commercialization of Cubicin® and its subsequent acquisition by Merck for approximately $9.5 billion, demonstrates his capability in driving company growth and market expansion, which will positively impact Immunic's future strategic development.
See More
Immunic Appoints New Chair of Board
- Leadership Change: Immunic, Inc. appointed Michael W. Bonney as Chair of the Board effective May 16, 2026, succeeding Simona Skerjanec, who will remain a board member, indicating a strategic leadership shift during a critical growth phase for the company.
- Extensive Industry Experience: Bonney brings over 30 years of leadership experience in the biopharmaceutical sector, having held senior commercial roles at Biogen where he was instrumental in launching Avonex®, which is expected to provide valuable insights for Immunic's product development and market strategies.
- Clinical Trial Progress: Immunic's lead development program, vidofludimus calcium, is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's market outlook.
- Clear Strategic Goals: Bonney expressed his commitment to supporting Immunic's regulatory and commercial strategies, particularly in the upcoming clinical trials and product launches, aiming to transition the company into a fully integrated commercial-stage entity.
See More
Immunic Q1 Earnings Miss Expectations with EPS of -$1.08
- Earnings Performance: Immunic reported a Q1 GAAP EPS of -$1.08, missing expectations by $0.12, indicating challenges in profitability that could affect investor confidence.
- Cash Reserves: As of March 31, 2026, Immunic had cash and cash equivalents of $186.6 million, which is expected to fund operations into late 2027, reflecting some flexibility in financial management.
- Impact of Financing Activities: The recent $400 million private placement provides crucial funding for R&D and operations, suggesting that despite short-term financial struggles, the company has long-term growth potential.
- Market Reaction: Immunic's stock rose following a new Buy rating from Guggenheim, indicating market confidence in its lead asset, even though overall financial data was disappointing.
See More
Immunic Appoints New CMO and Raises $200 Million in Financing
- Leadership Strengthening: Immunic has appointed renowned biopharmaceutical executive Dr. Michael A. Panzara as Chief Medical Officer, leveraging his extensive expertise in neurology to advance clinical development for multiple sclerosis treatments, thereby enhancing the company's competitive edge in this field.
- Clinical Trial Progress: The company is executing Phase 3 ENSURE trials for Vidofludimus Calcium, with top-line data expected by the end of 2026, a critical milestone that could pave the way for future drug applications and potential commercialization.
- Successful Financing: In February, Immunic closed an oversubscribed private placement raising $200 million, with the potential for an additional $200 million, signaling strong investor confidence and providing essential resources to support clinical trials and commercialization readiness.
- Significant Market Potential: As the first Nurr1 activator, Vidofludimus Calcium is expected to offer transformative potential in the global multiple sclerosis market, projected to exceed $30 billion by 2030, with the company's R&D efforts also expanding into other neurodegenerative diseases.
See More
Immunic Appoints New CMO and Raises $200 Million
- Leadership Change: Immunic appointed biopharmaceutical expert Dr. Michael A. Panzara as Chief Medical Officer to enhance the company's capabilities in clinical development and regulatory affairs in neurology, thereby strengthening its competitive position in multiple sclerosis treatment.
- Successful Financing: The company completed an oversubscribed private placement in February 2026, raising $200 million with a potential total of $400 million, providing ample funding to advance key clinical trials and prepare for commercialization.
- Clinical Trial Progress: The ongoing ENSURE Phase 3 clinical trials are expected to yield top-line data by the end of 2026, laying the groundwork for a drug application in the U.S. and furthering the company's strategic positioning in the multiple sclerosis market.
- Financial Performance: In Q1 2026, Immunic's R&D expenses reached $25.6 million, an increase of $4.1 million year-over-year, reflecting heightened investment in the development of its lead asset, vidofludimus calcium, despite a net loss of $32.6 million, indicative of its high-investment growth phase.
See More
Immunic, Inc. to Participate in Investor Conferences
- Clinical Trial Progress: Immunic, Inc.'s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which will establish a foundation for the company's future market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective, anti-inflammatory, and antiviral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), demonstrating potential across various neurological diseases.
- Diversified Development Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aimed at building a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune-related diseases, enhancing the company's competitive edge.
- Investor Conference Participation: Immunic will participate in several investor and medical conferences in May to showcase its development progress and future strategies, aiming to attract more investor attention and enhance the company's visibility in the biotechnology sector.
See More
Immunic Appoints New Chair of Board of Directors
- Leadership Change: Immunic, Inc. appointed Mike Bonney as Chair of the Board effective May 16, 2026, succeeding Interim Chair Simona Skerjanec; Bonney brings over 30 years of leadership experience in the biopharmaceutical industry, particularly in multiple sclerosis, which is expected to drive the company towards commercialization.
- Proven Success: Bonney's previous role at Biogen involved senior commercial leadership and the launch of Avonex®, a foundational therapy for multiple sclerosis, and this experience is anticipated to support Immunic's regulatory approval and market readiness for vidofludimus calcium.
- Market Potential: Immunic's vidofludimus calcium is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026; Bonney's addition is expected to enhance the company's competitiveness in this rapidly growing market.
- Strategic Development: Bonney's successful tenure at Cubist Pharmaceuticals, where he led the commercialization of Cubicin® and its subsequent acquisition by Merck for approximately $9.5 billion, demonstrates his capability in driving company growth and market expansion, which will positively impact Immunic's future strategic development.
See More
Immunic Appoints New Chair of Board
- Leadership Change: Immunic, Inc. appointed Michael W. Bonney as Chair of the Board effective May 16, 2026, succeeding Simona Skerjanec, who will remain a board member, indicating a strategic leadership shift during a critical growth phase for the company.
- Extensive Industry Experience: Bonney brings over 30 years of leadership experience in the biopharmaceutical sector, having held senior commercial roles at Biogen where he was instrumental in launching Avonex®, which is expected to provide valuable insights for Immunic's product development and market strategies.
- Clinical Trial Progress: Immunic's lead development program, vidofludimus calcium, is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact the company's market outlook.
- Clear Strategic Goals: Bonney expressed his commitment to supporting Immunic's regulatory and commercial strategies, particularly in the upcoming clinical trials and product launches, aiming to transition the company into a fully integrated commercial-stage entity.
See More
Immunic Q1 Earnings Miss Expectations with EPS of -$1.08
- Earnings Performance: Immunic reported a Q1 GAAP EPS of -$1.08, missing expectations by $0.12, indicating challenges in profitability that could affect investor confidence.
- Cash Reserves: As of March 31, 2026, Immunic had cash and cash equivalents of $186.6 million, which is expected to fund operations into late 2027, reflecting some flexibility in financial management.
- Impact of Financing Activities: The recent $400 million private placement provides crucial funding for R&D and operations, suggesting that despite short-term financial struggles, the company has long-term growth potential.
- Market Reaction: Immunic's stock rose following a new Buy rating from Guggenheim, indicating market confidence in its lead asset, even though overall financial data was disappointing.
See More
Immunic Appoints New CMO and Raises $200 Million in Financing
- Leadership Strengthening: Immunic has appointed renowned biopharmaceutical executive Dr. Michael A. Panzara as Chief Medical Officer, leveraging his extensive expertise in neurology to advance clinical development for multiple sclerosis treatments, thereby enhancing the company's competitive edge in this field.
- Clinical Trial Progress: The company is executing Phase 3 ENSURE trials for Vidofludimus Calcium, with top-line data expected by the end of 2026, a critical milestone that could pave the way for future drug applications and potential commercialization.
- Successful Financing: In February, Immunic closed an oversubscribed private placement raising $200 million, with the potential for an additional $200 million, signaling strong investor confidence and providing essential resources to support clinical trials and commercialization readiness.
- Significant Market Potential: As the first Nurr1 activator, Vidofludimus Calcium is expected to offer transformative potential in the global multiple sclerosis market, projected to exceed $30 billion by 2030, with the company's R&D efforts also expanding into other neurodegenerative diseases.
See More
Immunic Appoints New CMO and Raises $200 Million
- Leadership Change: Immunic appointed biopharmaceutical expert Dr. Michael A. Panzara as Chief Medical Officer to enhance the company's capabilities in clinical development and regulatory affairs in neurology, thereby strengthening its competitive position in multiple sclerosis treatment.
- Successful Financing: The company completed an oversubscribed private placement in February 2026, raising $200 million with a potential total of $400 million, providing ample funding to advance key clinical trials and prepare for commercialization.
- Clinical Trial Progress: The ongoing ENSURE Phase 3 clinical trials are expected to yield top-line data by the end of 2026, laying the groundwork for a drug application in the U.S. and furthering the company's strategic positioning in the multiple sclerosis market.
- Financial Performance: In Q1 2026, Immunic's R&D expenses reached $25.6 million, an increase of $4.1 million year-over-year, reflecting heightened investment in the development of its lead asset, vidofludimus calcium, despite a net loss of $32.6 million, indicative of its high-investment growth phase.
See More
Immunic, Inc. to Participate in Investor Conferences
- Clinical Trial Progress: Immunic, Inc.'s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which will establish a foundation for the company's future market performance.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective, anti-inflammatory, and antiviral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), demonstrating potential across various neurological diseases.
- Diversified Development Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aimed at building a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune-related diseases, enhancing the company's competitive edge.
- Investor Conference Participation: Immunic will participate in several investor and medical conferences in May to showcase its development progress and future strategies, aiming to attract more investor attention and enhance the company's visibility in the biotechnology sector.
See More
